1. Deutsche Bank
Health Care Conference
Cavan M. Redmond
Executive Vice President, General Manager
BioPharma Business Unit
May 3, 2007

2. Forward-Looking Statement
The statements in this presentation that are not historical facts are forward-
looking statements based on current expectations of future events that
involve risks and uncertainties including, without limitation, risks
associated with the inherent uncertainty of pharmaceutical research,
product development, manufacturing, commercialization, economic
conditions including interest and currency exchange rate fluctuations, the
impact of competitive or generic products, product liability and other types
of lawsuits, the impact of legislative and regulatory compliance and
obtaining approvals, and patent, and other risks and uncertainties,
including those detailed from time to time in Wyeth’s periodic reports,
including quarterly reports on Form 10-Q and the annual report on Form 10-
K, filed with the Securities and Exchange Commission. Quarterly results, in
particular, can vary due to issues which include, but are not limited to,
changes in exchange rates, the timing of actions taken by the Company to
ensure long-term improvements to our manufacturing processes, the
timing of regulatory approval of new products and/or facilities and the
timing of promotional programs. Actual results may vary materially from
the forward-looking statements. The Company assumes no obligation to
publicly update any forward-looking statements, whether as a result of new
information, future events or otherwise.

3. Biotechnology: Three Key Areas for Success
Ability to Globally
Commercialize Products
Expertise in Process Development
and Commercial Manufacturing
Ability to Create a Sustainable
Biotech R&D Pipeline

4. Biotech’s Unique Position in Healthcare
Only 227 Commercial Biotech Products on the Market
n
Today
The Top 10 Biotech Companies Accounted for 100 of
n
the 227 Biotech Products on the Market in 2006
Ex-US Markets Have Become Important Biotech
n
Markets
Wyeth Has Two Top 20 Biotech Products:
n
4Enbrel
4Prevnar

5. Biotech Industry – Top 10 Companies
Wyeth Ranks 4th in Audited Sales
MAT/12/2006 MAT/12/2006
Rank (000's)
Total Biotech Industry $ 76,535,257
Top 10 Biotech Companies $ 54,302,797
AMGEN 1 $ 15,895,830
ROCHE 2 $ 13,342,857
JOHNSON & JOHNSON 3 $ 6,751,136
WYETH+ENBREL* 4 $ 6,275,683
NOVARTIS 5 $ 3,055,300
NOVO NORDISK 6 $ 3,041,482
GILEAD SCIENCES 7 $ 2,331,733
LILLY 8 $ 2,265,241
SANOFI-AVENTIS 9 $ 2,156,318
SCHERING-PLOUGH 10 $ 2,149,310
*Enbrel for North America included in both Wyeth and Amgen; however, industry number does not double count Enbrel.
Source: Market Insights; IMS Quarterly Midas; Biotech industry based on definition by biotechnology industry organization, www.bio.org.

6. Wyeth is 3rd of Top 10 Pharma Companies in Biotech
Audited Sales as a Percentage of the Business
MAT/12/2006 MAT/12/2006 Percent
Rank ('000's) Biotech
Global Rx Industry $ 552,691,651 14%
Global Biotech Industry $ 76,535,257 NA
PFIZER 1 $ 45,061,752 2%
GLAXOSMITHKLINE 2 $ 35,134,973 3%
SANOFI-AVENTIS 3 $ 29,058,798 7%
NOVARTIS 4 $ 28,826,878 11%
ASTRAZENECA 5 $ 26,389,075 0%
MERCK & CO 6 $ 24,734,873 1%
JOHNSON & JOHNSON 7 $ 22,662,100 30%
ROCHE 8 $ 21,371,780 62%
WYETH+ENBREL+ALTACE* 9 $ 17,971,027 35%
AMGEN 10 $ 15,992,680 99%
ABBOTT 11 $ 15,912,513 13%
*Enbrel for North America included in both Wyeth and Amgen; however, industry number does not double count Enbrel.
Source: Market Insights; IMS Quarterly Midas; Biotech industry based on definition by Biotechnology Industry Organization, www.bio.org.

7. Wyeth Biotech Results
2007 1Q
GROWTH
Wyeth Biotech Worldwide Revenue 1Q07 vs.
1Q06
$1.7 Billion – 1Q2007
1Q07 + 39%
Biotech Reported Solid Results for 1Q07

8. Wyeth Biotech – A Global Reach
2007 1Q Results
Growth vs. 1Q06
Asia Pacific
$83M
92%
92%
Latin
America
$73M
EMEA-
EMEA -
45%
45%
Canada
34%
34%
$702M
16%
16%
US Region
$847M
US EMEA Asia Latin
Region CA Pacific America

9. Wyeth Biotech Net Revenue Results
2007 1Q Key Growth Drivers
49%
43%
33%
13%
$617M
$445M
$177M
$97M
(Ex North America)
Represents 1Q2007 Net Revenue and percentage increase compared with prior year.
Infuse/Inductos (BMP) represents Net Revenue reported by Wyeth for US sales recorded by MSD.

10. Wyeth in Biotech: Global Growth Resulting in Two
Products Reaching/Exceeding $3 Billion in 2010
Enbrel: $3 Billion Ex-US
n
4Market Opportunities
4Geographic and Medical Expansion
4Unique Mechanism of Action With Extensive Safety/Efficacy
Prevnar: Double Sales From 2005 to 2010
n
4Launches in New Countries
4National Immunization Programs

11. Enbrel – Second Largest Global Biotech
Brand (Audited Sales)
MAT/12/2006 MAT/12/2006
Rank ('000's)
Selected Market $ 76,535,257
ARANESP 1 $ 4,964,712
ENBREL 2 $ 4,518,925
ERYPO 3 $ 3,661,877
REMICADE 4 $ 3,560,530
NEULASTA 5 $ 3,249,424
MABTHERA 6 $ 3,206,692
EPOGEN 7 $ 3,142,188
Enbrel Remains One of Top 10
Pharmaceutical Products Worldwide

12. Prevnar®
Launched in 76 Countries
Additional 9 Launches
by 2008

13. National Immunization Programs
Current NIPs Potential NIPs
Netherlands Austria New Zealand
United States n n n
n
Norway Denmark Portugal
Australia n n n
n
Qatar Finland Saudi Arabia
Canada n n n
n
Switzerland Hong Kong Singapore
France n n n
n
United Kingdom Iceland South Korea
Germany n n n
n
Mexico Ireland Spain
Greece n n n
n
Italy Japan Sweden
Kuwait n n n
n
Belgium Taiwan Costa Rica
Luxembourg n n n
n
Total Birth Cohort ~10 Million Total Birth Cohort ~3 Million

14. Emerging Market Opportunities
Private to Potential NIPs Private Markets
Argentina Chile Peru
n n n
China Philippines
Brazil n n
n
Colombia Ecuador Romania
n n n
Hungary Russia
Czech Republic n n
n
Poland India South Africa
n n n
Indonesia Thailand
Turkey n n
n
Uruguay
Venezuela Malaysia n
n n
Pakistan
n
Total Birth Cohort ~58 Million
Total Birth Cohort ~8 Million

15. Hemophilia Franchise: Driving New Innovation
The Only Recombinant Factor
Recombinant FVIII n
n
IX
ReFacto AF
n
A New Formulation of
n
4New Albumin-Free ReFacto BeneFIX Expected to Launch
Mid-2007
4Manufactured Using No
Human or Animal Products 4Key Additional Convenience
4Filed 2Q07 Devices to Meet Patient’s
Needs
Additional Convenience
n
Full European Rights Revert to
Devices to Meet Patient’s n
Wyeth in July 2007
Needs

16. BMP-2: Innovating Biotech & Devices
INFUSE Sales
Indications
(As Reported by Medtronic)
2004: Open
2002: Spinal
$700
Tibia Fracture
Fusion + 30%
0%
$600
~5
: + 41%
GR
CA
$500
$ mil
+ 102%
$400
$300
$200
Revolutionary Product Meeting
n
Significant Medical Needs $100
Oral Maxillofacial Procedures
n
$0
4 Approved by FDA in March 2007
2003 2004 2005 2006
AMPLIFY for Posterolateral
n
Spinal Fusion
4 Submitted to and Accepted by FDA in Q1 2006

17. Algete, Spain Andover, MA
Algete, Spain Andover, MA
Grange Castle, Ireland
Grange Castle, Ireland
Pearl River, NY Sanford, NC
Pearl River, NY Sanford, NC

18. Biology Over Stainless Steel
Our Current Investments Are in Process
n
Standardization and Upstream/Downstream
Process Efficiencies and Yields
Upstream: Proprietary Position on Enhancing
n
Cell Culture Yields With Defined Media (2004) CHO Chip Scan
4 “Wyeth Recently Created a Cell Culture System
That Can Generate 9 Grams of Protein Per Liter
of Culture. Just Four Years Ago, the Standard
Was 1 Gram Per Liter.” Nature Biotechnology,
September 2006
We Are Focused on Further CHO Cell
n
Improvement Through Genetic and Metabolic
Engineering (Gene Chip)

19. Changing the Paradigm of Biotech
Manufacturing Capacity
DOWNSTREAM: Proprietary
n
Position on Two-Column
Purification for Mabs (2005)
All Proprietary Processes
n
Incorporated Into Standardized
Platform
4 Speed to IND and Launch
10 Metric Tons of Theoretical
n
Capacity From Standard
Facilities
4 Or 1 Metric Ton X 4 Products -
Sept 2006 ACS in SF
Transforms the Thinking on
n
Cost Structure and Importance
of Volumetric Capacity

20. A Robust Biotech Pipeline Contributing
to Future Growth
1/3 of Current Pipeline Is
Phase 0 Phase 1 Phase 2 Phase 3 Registration n
Biotech and Vaccines
Mylotarg ® – AML
CME-548 Inotuzumab/ Bapineuzumab 13vPnC Infant
Torisel™
AAB-002 (CMC-544) GAP-486 13vPnC Adult
Combination of In-house
ReFacto® AF
TRU-015 (Onc) IMA-638 TRU-015 (RA) n
IMA – 026 ILV-094 BMP-2 Inject.
and In-licensing
ILV-095 MnB Infant MYO-029
RAS -072 ACC-001 MnB Adolescent
SBI -087
Broad Therapeutic
n
BLD-089
BMP-12
Coverage
BHS-019
ACC-002
4 Immunology
HIV Vaccine (4)
Staph aureus
4 Vaccines
4 Oncology
4 Bone Growth
Proteins
4 Neuroscience
Vaccines
4 Hemophilia
Our Discovery Pipeline Continues To Grow

21. Biotech at Wyeth – A Look At the Future
45%
45%
2010
33%
33% (est.)
(est.)
14%
14% 2006
2000